EA200301253A1 - Применение остеопонтина для лечения и/или профилактики неврологических заболеваний - Google Patents

Применение остеопонтина для лечения и/или профилактики неврологических заболеваний

Info

Publication number
EA200301253A1
EA200301253A1 EA200301253A EA200301253A EA200301253A1 EA 200301253 A1 EA200301253 A1 EA 200301253A1 EA 200301253 A EA200301253 A EA 200301253A EA 200301253 A EA200301253 A EA 200301253A EA 200301253 A1 EA200301253 A1 EA 200301253A1
Authority
EA
Eurasian Patent Office
Prior art keywords
osteopontin
neurological diseases
prevention
treatment
application
Prior art date
Application number
EA200301253A
Other languages
English (en)
Other versions
EA006655B1 (ru
Inventor
Урсула Бошерт
Георг Фегер
Рагхурам Селвараджу
Рубен Папоян
Лилия Бернаскони
Original Assignee
Апплайд Резеч Системз Арс Холдинг Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Апплайд Резеч Системз Арс Холдинг Н.В. filed Critical Апплайд Резеч Системз Арс Холдинг Н.В.
Publication of EA200301253A1 publication Critical patent/EA200301253A1/ru
Publication of EA006655B1 publication Critical patent/EA006655B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

Настоящее изобретение относится к применению остеопонтина или агониста активности остеопонтина для лечения или профилактики неврологических заболеваний.Отчет о международном поиске был опубликован 2003.03.06.
EA200301253A 2001-05-17 2002-05-08 Применение остеопонтина для лечения и/или профилактики неврологических заболеваний EA006655B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01111296 2001-05-17
PCT/EP2002/005081 WO2002092122A2 (en) 2001-05-17 2002-05-08 Use of osteopontin for the treatment and/or prevention of neurologic diseases

Publications (2)

Publication Number Publication Date
EA200301253A1 true EA200301253A1 (ru) 2004-06-24
EA006655B1 EA006655B1 (ru) 2006-02-24

Family

ID=8177366

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200301253A EA006655B1 (ru) 2001-05-17 2002-05-08 Применение остеопонтина для лечения и/или профилактики неврологических заболеваний

Country Status (26)

Country Link
US (4) US7217687B2 (ru)
EP (1) EP1389130B1 (ru)
JP (2) JP4417632B2 (ru)
KR (1) KR100947424B1 (ru)
CN (2) CN1939538A (ru)
AT (1) ATE555803T1 (ru)
AU (1) AU2002312886B2 (ru)
BG (1) BG108337A (ru)
BR (1) BR0209812A (ru)
CA (1) CA2443964A1 (ru)
CZ (1) CZ20033109A3 (ru)
EA (1) EA006655B1 (ru)
EE (1) EE200300559A (ru)
ES (1) ES2387082T3 (ru)
HR (1) HRP20030840A2 (ru)
HU (1) HUP0400005A3 (ru)
IL (2) IL158867A0 (ru)
MX (1) MXPA03010327A (ru)
NO (1) NO20035025D0 (ru)
NZ (1) NZ528852A (ru)
PL (1) PL211763B1 (ru)
SK (1) SK14232003A3 (ru)
UA (1) UA85368C2 (ru)
WO (1) WO2002092122A2 (ru)
YU (1) YU89503A (ru)
ZA (1) ZA200307956B (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1389306A2 (de) * 2001-05-09 2004-02-18 BioVisioN AG Verfahren zum nachweis einer progedienten, chronisch-demenziellen erkrankung, zugehörige peptide und nachweisreagenzien
AU2002357748A1 (en) * 2001-11-21 2003-06-10 The Board Of Trustees Of The Leland Stanford Junior University Osteopontin-related compositions and methods
EP1517695A4 (en) * 2002-06-25 2010-09-01 Aventis Pharma Inc OSTEOPONTIN, OLIGODENDROCYTES AND MYELINATION
US7678889B2 (en) * 2002-08-06 2010-03-16 Diadexus, Inc. Compositions and methods relating to ovarian specific genes and proteins
CN1791422A (zh) * 2003-03-28 2006-06-21 应用研究系统Ars股份公司 凝聚素在治疗和/或预防周围神经疾病中的用途
MXPA06003117A (es) * 2003-09-18 2009-09-04 Arla Foods Amba Formula infantil.
EP1684797A1 (en) 2003-11-12 2006-08-02 Yeda Research and Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
WO2006087579A1 (en) * 2005-02-18 2006-08-24 Proximagen Ltd. Treatment for neurodegeneration
US20060264371A1 (en) * 2005-02-18 2006-11-23 Proximagen Ltd. Treatment
AU2006304274B2 (en) 2005-10-13 2012-08-16 Celularity Inc. Production of oligodendrocytes from placenta-derived stem cells
EP1870107A1 (en) * 2006-06-23 2007-12-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of inducer of promyelocytic leukemia protein (PML) for treating polyglutamine expansion neurodegenerative diseases
WO2008086449A2 (en) * 2007-01-09 2008-07-17 Oregon Health & Science University Synthetic osteopontin peptides and methods of use
US20100069254A1 (en) * 2008-09-16 2010-03-18 Laree Hiser Cell Culture Model for Demyelination/Remyelination
KR101449100B1 (ko) * 2011-04-21 2014-10-13 가톨릭대학교 산학협력단 신경세포 데브리스 제거용 오스테오폰틴
GB2493540A (en) * 2011-08-10 2013-02-13 Follicum Ab Agents for stimulating hair growth in mammals
WO2014051398A1 (ko) * 2012-09-28 2014-04-03 한국생명공학연구원 아세카이니드 또는 이의 유도체를 포함하는 근력약화 관련 질환의 예방 또는 치료용 약학적 조성물
AU2015308899B2 (en) * 2014-08-27 2020-05-28 Dana-Farber Cancer Institute, Inc. Intracellular osteopontin regulates the lineage commitment of lymphoid subsets
EP3458036B1 (en) * 2016-05-20 2023-08-23 Cedars-Sinai Medical Center Treating or preventing alzheimer's disease and associated conditions
US10954280B2 (en) * 2016-11-27 2021-03-23 Triton Algae Innovations, Inc. Method of purification of recombinant osteopontin from micro algae
CN110545834B (zh) 2017-05-04 2024-02-20 富力卡姆股份公司 用于治疗糖尿病的肽
US11484576B2 (en) * 2017-08-15 2022-11-01 The Children's Medical Center Corporation Methods of promoting corticospinal neuronal outgrowth in neuronal lesions using a pro-regenerative human osteopontin fragment
WO2019226643A1 (en) * 2018-05-25 2019-11-28 The Children's Medical Center Corporation Methods for treating spinal cord injury
TR201903865A2 (tr) * 2019-03-14 2020-09-21 Bogazici Ueniversitesi Amyotrofi̇k lateral skleroz tedavi̇si̇ i̇çi̇n i̇nterferon kullanimi
WO2021024265A1 (en) * 2019-08-08 2021-02-11 Ramot At Tel-Aviv University Ltd. Methods of treating non-infectious inflammatory disorders
CN111388654A (zh) * 2020-05-22 2020-07-10 南通大学 治疗脊髓损伤的药物、药物试剂盒及方法
US20230265435A1 (en) * 2020-06-02 2023-08-24 The Catholic University Of Korea Industry-Academic Cooperation Foundation Composition comprising osteopontin inhibitor as active ingredient for prevention, alleviation, or treatment of neurodegenerative disease
CN117720620B (zh) * 2023-12-13 2024-07-23 无锡市儿童医院 小分子多肽和其药物组合物、其制药用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2016953A3 (en) 1998-12-22 2009-04-15 Genentech, Inc. Vascular endothelial cell growth factor antagonists and uses thereof
IL145891A0 (en) 1999-04-15 2002-07-25 Childrens Medical Center Methods and compositions for modulating an immune response
WO2000064460A2 (en) * 1999-04-23 2000-11-02 Sulzer Orthopedics Ltd. Composition for enhancing functional recovery of a mammal from central and/or peripheral nervous system injury of traumatic or pathological origin
MXPA02003176A (es) 1999-10-04 2002-09-30 Shearwater Corp Neuropeptidos estabilizados por polimero.

Also Published As

Publication number Publication date
ZA200307956B (en) 2004-10-13
EP1389130B1 (en) 2012-05-02
AU2002312886B2 (en) 2007-10-25
JP4417632B2 (ja) 2010-02-17
HK1067051A1 (en) 2005-04-01
YU89503A (sh) 2006-05-25
IL158867A0 (en) 2004-05-12
IL158867A (en) 2010-05-17
WO2002092122A2 (en) 2002-11-21
ATE555803T1 (de) 2012-05-15
US20080213234A1 (en) 2008-09-04
HUP0400005A3 (en) 2012-09-28
ES2387082T3 (es) 2012-09-13
NZ528852A (en) 2005-12-23
US20070225214A1 (en) 2007-09-27
BG108337A (bg) 2004-12-30
KR100947424B1 (ko) 2010-03-12
EE200300559A (et) 2004-02-16
UA85368C2 (ru) 2009-01-26
US20040235720A1 (en) 2004-11-25
MXPA03010327A (es) 2004-02-17
KR20040008176A (ko) 2004-01-28
CZ20033109A3 (en) 2004-06-16
CN1533283A (zh) 2004-09-29
JP2004536058A (ja) 2004-12-02
PL367065A1 (en) 2005-02-21
SK14232003A3 (sk) 2004-05-04
JP2009191082A (ja) 2009-08-27
US20050176639A1 (en) 2005-08-11
BR0209812A (pt) 2004-06-01
WO2002092122A3 (en) 2003-03-06
PL211763B1 (pl) 2012-06-29
NO20035025L (no) 2003-11-12
CN1939538A (zh) 2007-04-04
CA2443964A1 (en) 2002-11-21
NO20035025D0 (no) 2003-11-12
EP1389130A2 (en) 2004-02-18
HUP0400005A2 (hu) 2004-04-28
US7217687B2 (en) 2007-05-15
JP5036761B2 (ja) 2012-09-26
HRP20030840A2 (en) 2005-08-31
CN1286524C (zh) 2006-11-29
EA006655B1 (ru) 2006-02-24
US7297099B2 (en) 2007-11-20

Similar Documents

Publication Publication Date Title
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
EA200200208A1 (ru) Синергитическая композиция
EA200100822A1 (ru) Baff, относящиеся к нему блокирующие агенты и их применение в стимуляции и ингибировании b-клеток и иммуноглобулинов в иммунных реакциях
EA200400735A1 (ru) 3-β-D-РИБОФУРАНОЗИЛТИАЗОЛО[4,5-d]ПИРИМИДИННУКЛЕОЗИДЫ И ИХ ПРИМЕНЕНИЯ
EA200401341A1 (ru) Применение остеопротегерина для лечения и/или профилактики фиброзного заболевания
EA199900324A1 (ru) Комбинированная терапия для лечения психозов
EA200100780A1 (ru) Антагонисты tweak и рецептора tweak и их использование для лечения иммунологических заболеваний
ITMI20010562A1 (it) Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
EA200300953A1 (ru) Терапевтические комбинации для применения при сердечно-сосудистых и воспалительных заболеваниях
NO20034056D0 (no) Proliferative sykdommer
EA200500856A1 (ru) Новые химические соединения
ATE321048T1 (de) Beta-amino-tetrahydroimidazo(1,2-a)pyrazine und - tetrahydrotriazolo(4,3-a)pyrazine als dipeptidyl peptidase inhibitoren zur behandlung oder prevention von diabetes
EA200400586A1 (ru) Замещённые тиоацетамиды
DE69938179D1 (de) Kombination von riluzol und levodopa zur behandlung von morbus parkinson
EA200401183A1 (ru) Применение ингибиторов il-18 в качестве диагностического маркера
ATE369130T1 (de) Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen
EA200501479A1 (ru) Ifn-бета в отдельности или в комбинации с другими лекарственными средствами для лечения болезни альцгеймера и нарушений, связанных с деменцией
EA200500803A1 (ru) Антагонисты ccr1 для лечения воспалительных артритов, демиелинизационных воспалительных заболеваний
EA200000741A1 (ru) Новые производные дигидроксигексановой кислоты
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
EA200501528A1 (ru) Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
EA200400296A1 (ru) Применение ингибиторов il-18 при расстройствах в виде гиперчувствительности

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
PD4A Registration of transfer of a eurasian patent in accordance with the succession in title
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU